iHub News
2月前
Allogene Publishes Promising ALLO-329 Data in Nature CommunicationsApril 15, 2026 10:59 AM
IH Market News
Allogene Therapeutics (NASDAQ:ALLO) said new pre-clinical data for its investigational CAR-T therapy ALLO-329 have been published in Nature Communications, highlighting a dual-targeting approach aimed at treating autoimmune diseases.ALLO-329 is an allogeneic, off-the-shelf CAR-T candidate designed to target both CD19-positive B cells and CD70-positive activated T cells, two key drivers of autoimmune conditions. The data showed the therapy maintained strong anti-CD19 activity while avoiding immune rejection and promoting CAR-T cell expansion.The dual-targeting design also demonstrated improved effectiveness in tumor models with antigen loss and reduced antibody levels in autoimmune disease models, suggesting potential for broader therapeutic impact.The findings further support the company’s Dagger® technology, which is intended to enhance CAR-T cell persistence and potentially reduce or eliminate the need for traditional lymphodepletion, a key barrier in current treatments.“The preclinical data published in Nature Communications highlight the potential of ALLO-329’s dual-targeting approach to address both B- and T-cell drivers of autoimmune disease,” said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. “By combining precision targeting with an off-the-shelf platform, we believe ALLO-329 has the potential to deliver a more complete and scalable treatment approach without the need for intensive lymphodepletion. We are excited to advance this program and explore its potential across a range of autoimmune diseases.”Allogene is currently evaluating ALLO-329 in its Phase 1 RESOLUTION trial, which is enrolling patients with conditions including lupus, scleroderma and inflammatory myositis. The study is testing multiple dose levels, starting at 20 million CAR-T cells, across cohorts receiving reduced or no lymphodepletion.Initial data from the first cohort are expected in June 2026, with further updates anticipated later in the year.ALLO-329 has already received Fast Track designation from the U.S. Food and Drug Administration for multiple autoimmune indications, including lupus, myositis and scleroderma.If successful, the therapy could open a significant new market for cell therapies, particularly given its scalable manufacturing model and potential for broader accessibility compared with existing approaches.Allogene Therapeutics stock price
Original: Allogene Publishes Promising ALLO-329 Data in Nature Communications
iHub News
2月前
Allogene shares jump on encouraging ALPHA3 trial updateApril 13, 2026 10:13 AM
IH Market News
Allogene Therapeutics (NASDAQ:ALLO) surged 36% on Monday after releasing positive interim data from its pivotal ALPHA3 study, showing that cemacabtagene ansegedleucel (cema-cel) delivered significantly higher minimal residual disease (MRD) clearance rates compared with observation.The interim futility analysis revealed MRD clearance of 58.3% in the cema-cel arm versus 16.7% in the observation group, representing a 41.6% absolute improvement—well above the 25–30% threshold considered clinically meaningful in existing literature. The study focuses on patients undergoing first-line consolidation for large B-cell lymphoma.At the first MRD assessment on Day 45, circulating tumor DNA (ctDNA) levels dropped by a median of 97.7% in patients treated with cema-cel, while the observation arm showed a median increase of 26.6%. The findings were based on 24 patients, evenly split between the two groups.Safety data also appeared favorable, with no reported cases of cytokine release syndrome, neurotoxicity, graft-versus-host disease, or treatment-related serious adverse events. Notably, 10 of the 12 patients receiving cema-cel were managed entirely in outpatient settings following infusion.Community cancer centers played a notable role in the study, accounting for around one-third of both patient screening and treatment administration, including sites with limited prior experience in CAR T therapies.The ALPHA3 trial is currently underway at more than 60 sites and aims to enroll approximately 220 patients. Recruitment is expected to conclude by the end of 2027, with an interim analysis of event-free survival (EFS) planned for mid-2027 and the primary EFS readout targeted for mid-2028.Event-free survival is the primary endpoint of the study, with progression-free survival and overall survival among the key secondary measures. The trial is designed to demonstrate a 50% reduction in the risk of EFS events, defined as the need for new anti-lymphoma therapy, disease progression, or death.Allogene Therapeutics stock price
Original: Allogene shares jump on encouraging ALPHA3 trial update
georgie18
1年前
ALLO...$2.35...🥳...Nice move off the $1.80 Range Bottom...
georgie18
Member Level
Re: georgie18 post# 387047
Thursday, January 02, 2025 9:51:39 AM
Post#
387852
of 388270
ALLO...$2.20s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 667756
Monday, December 16, 2024 2:11:12 PM
Post#
667880
of 670030
ALLO...$2.08...🥳...Reversal Candle off the $1.80 range bottom...
georgie18
Member Level
Re: georgie18 post# 385710
Friday, December 13, 2024 2:38:52 PM
Post#
386948
of 387046
ALLO...$1.85...🥳Look like tax selling to me...Scooping up the dip...
georgie18
Member Level
Re: georgie18 post# 664158
Friday, November 15, 2024 11:35:10 AM
Post#
665142
of 667755
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...
georgie18
1年前
ALLO...$2.20s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 667756
Monday, December 16, 2024 2:11:12 PM
Post#
667880
of 670030
ALLO...$2.08...🥳...Reversal Candle off the $1.80 range bottom...
georgie18
Member Level
Re: georgie18 post# 385710
Friday, December 13, 2024 2:38:52 PM
Post#
386948
of 387046
ALLO...$1.85...🥳Look like tax selling to me...Scooping up the dip...
georgie18
Member Level
Re: georgie18 post# 664158
Friday, November 15, 2024 11:35:10 AM
Post#
665142
of 667755
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...
georgie18
2年前
ALLO...$3.31...Fins after todays close...🥳
georgie18
Member Level
Re: georgie18 post# 385280
Wednesday, November 06, 2024 10:27:01 AM
Post#
385286
of 385334
ALLO...$3.22s clearing here...🥳...Looking for the $5.78 Breakout... https://schrts.co/wITCFkcf
georgie18
Member Level
Re: georgie18 post# 663758
Wednesday, November 06, 2024 10:06:32 AM
Post#
663791
of 663807
ALLO...$3.17...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 385240
Wednesday, November 06, 2024 7:12:20 AM
Post#
385251
of 385279
ALLO...$3.10...🥳
georgie18
Member Level
Re: georgie18 post# 663652
Tuesday, November 05, 2024 3:37:32 PM
Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳
georgie18
Member Level
Re: georgie18 post# 385217
Tuesday, November 05, 2024 9:15:04 AM
Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
georgie18
2年前
ALLO...$3.22s clearing here...🥳...Looking for the $5.78 Breakout... https://schrts.co/wITCFkcf
georgie18
Member Level
Re: georgie18 post# 663758
Wednesday, November 06, 2024 10:06:32 AM
Post#
663791
of 663807
ALLO...$3.17...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 385240
Wednesday, November 06, 2024 7:12:20 AM
Post#
385251
of 385279
ALLO...$3.10...🥳
georgie18
Member Level
Re: georgie18 post# 663652
Tuesday, November 05, 2024 3:37:32 PM
Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳
georgie18
Member Level
Re: georgie18 post# 385217
Tuesday, November 05, 2024 9:15:04 AM
Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
georgie18
2年前
ALLO...$3.17...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 385240
Wednesday, November 06, 2024 7:12:20 AM
Post#
385251
of 385279
ALLO...$3.10...🥳
georgie18
Member Level
Re: georgie18 post# 663652
Tuesday, November 05, 2024 3:37:32 PM
Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳
georgie18
Member Level
Re: georgie18 post# 385217
Tuesday, November 05, 2024 9:15:04 AM
Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
georgie18
2年前
ALLO...$3.10...🥳
georgie18
Member Level
Re: georgie18 post# 663652
Tuesday, November 05, 2024 3:37:32 PM
Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳
georgie18
Member Level
Re: georgie18 post# 385217
Tuesday, November 05, 2024 9:15:04 AM
Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
georgie18
2年前
ALLO...$3 ...starting up again...🥳
georgie18
Member Level
Re: georgie18 post# 385217
Tuesday, November 05, 2024 9:15:04 AM
Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
georgie18
2年前
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
georgie18
2年前
ALLO...$3 Hitting again...🥳
georgie18
Member Level
Re: georgie18 post# 41
Friday, September 27, 2024 3:57:49 PM
Post#
42
of 42
ALLO...$2.90...Setting up for the $3 Break again...🥳
georgie18
Member Level
Re: georgie18 post# 658272
Wednesday, September 25, 2024 10:03:06 AM
Post#
659219
of 659662
ALLO...$2.65...added more here on the dip...🥳
georgie18
Member Level
Re: None
Wednesday, September 18, 2024 1:30:50 PM
Post#
40
of 40
ALLO...$2.79 added the dip ...🥳
georgie18
2年前
ALLO...$2.98...W pattern still in play here...Looking for $3.23 Break...🥳off the $2.55 alert...
georgie18
Member Level
Re: georgie18 post# 36
Wednesday, September 11, 2024 4:02:04 PM
Post#
38
of 38
ALLO...$2.92...Psar flipped Bullish...Trying for upper bollie break...🥳...
georgie18
Member Level
Re: georgie18 post# 652456
Monday, August 26, 2024 2:22:57 PM
Post#
655267
of 657175
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳
georgie18
Member Level
Re: georgie18 post# 32
Thursday, August 22, 2024 9:38:16 AM
Post#
33
of 35
ALLO...$2.72s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 652456
Monday, August 19, 2024 3:08:16 PM
Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳
georgie18
Member Level
Re: None
Tuesday, August 06, 2024 1:20:27 PM
Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
georgie18
2年前
ALLO...$2.92...Psar flipped Bullish...Trying for upper bollie break...🥳...
georgie18
Member Level
Re: georgie18 post# 652456
Monday, August 26, 2024 2:22:57 PM
Post#
655267
of 657175
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳
georgie18
Member Level
Re: georgie18 post# 32
Thursday, August 22, 2024 9:38:16 AM
Post#
33
of 35
ALLO...$2.72s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 652456
Monday, August 19, 2024 3:08:16 PM
Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳
georgie18
Member Level
Re: None
Tuesday, August 06, 2024 1:20:27 PM
Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
georgie18
2年前
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳
georgie18
Member Level
Re: georgie18 post# 32
Thursday, August 22, 2024 9:38:16 AM
Post#
33
of 35
ALLO...$2.72s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 652456
Monday, August 19, 2024 3:08:16 PM
Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳
georgie18
Member Level
Re: None
Tuesday, August 06, 2024 1:20:27 PM
Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳
Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
glenn1919
1月前
EarningsCentral
3月前
Monksdream
1年前
TrendTrade2016
2年前
Mactheriverrat
2年前
glens0
2年前
メールアドレスで登録
